Erste Asset Management’s Atara Biotherapeutics ATRA Stock Holding History

Erste Asset Management’s Portfolio ATRA Stock Details ATRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-880	Closed	-$35.9K	–	547
2023 Q2	$35.9K	Hold	880	–	–	﹤0.01%	546
2023 Q1	$61.6K	Hold	880	–	–	﹤0.01%	543
2022 Q4	$69.1K	Hold	880	–	–	﹤0.01%	540
2022 Q3	$79.9K	Hold	880	–	–	﹤0.01%	527
2022 Q2	$167K	Hold	880	–	–	﹤0.01%	522
2022 Q1	$202K	Hold	880	–	–	﹤0.01%	505
2021 Q4	$375K	Hold	880	–	–	0.01%	448
2021 Q3	$386K	Hold	880	–	–	0.01%	439
2021 Q2	$342K	Hold	880	–	–	0.01%	444
2021 Q1	$313K	Hold	880	–	–	0.01%	424
2020 Q4	$449K	Buy	+880	New	+$406K	0.01%	397

Other funds holding ATRA

Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Erste Asset Management's ATRA Position: Q3 2023 in Review

Erste Asset Management sold out of Atara Biotherapeutics (ATRA) in Q3 2023, closing a stake of 880 shares — an estimated $35.9K sold.

Erste Asset Management first reported a position in ATRA in Q4 2020 and held it in 11 quarters. The position peaked at $449K in Q4 2020. 109 funds tracked by Wall St. Rank hold ATRA as of Q3 2023.

Erste Asset Management reported no remaining Atara Biotherapeutics position as of Q3 2023 after selling out during the quarter.
Erste Asset Management sold 880 Atara Biotherapeutics shares in Q3 2023, an estimated $35.9K.
Erste Asset Management first reported a position in Atara Biotherapeutics in Q4 2020 and held it in 11 quarters.
Erste Asset Management's Atara Biotherapeutics position peaked at $449K in Q4 2020.
109 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q3 2023.

Based on Erste Asset Management's 13F filing for Q3 2023, filed 26 Nov 2024.